Friday, August 22, 2008 5:37:35 PM
I am still surprised - bordering in skepticism - at this analysis/conclusion.
I mean, what then is the point of such a safety study, if they are chcking for the "big-C" potential, with such a wide confidence interval ?
And an even more obvious question, why spare the rats ? They breed a lot faster than goats, right ?
"....on the biotech battle-field, you need some élan...."
Recent RPRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:20:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:19:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:17:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 01:02:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:20:53 AM
- Royalty Pharma Reports Second Quarter 2024 Results • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:04:01 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/29/2024 08:30:11 PM
- Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital • GlobeNewswire Inc. • 07/24/2024 12:30:00 PM
- Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 • GlobeNewswire Inc. • 07/19/2024 12:15:00 PM
- Royalty Pharma Declares Third Quarter 2024 Dividend • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:03:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:58:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:06:32 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/04/2024 09:12:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:57:02 PM
- Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 08:15:00 PM
- Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes • GlobeNewswire Inc. • 06/03/2024 09:15:27 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 06/03/2024 08:59:57 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/03/2024 01:13:40 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 06/03/2024 12:39:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 09:25:01 PM
- Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million • GlobeNewswire Inc. • 05/28/2024 11:10:00 AM
- Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline • GlobeNewswire Inc. • 05/22/2024 08:10:00 PM
- Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline • GlobeNewswire Inc. • 05/22/2024 08:00:00 PM
FEATURED POET Technologies Reports Second Quarter 2024 Financial Results • Aug 15, 2024 8:04 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
ATWEC Reaches Profitability, Announces Massive Earnings Growth, and a Strong Forecast for the Rest of 2024 • ATWT • Aug 15, 2024 7:16 AM